The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an antidepressant drug in improving depressive symptoms in participants with Major Depressive Disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI); and to assess the safety and tolerability of JNJ-42847922 compared to placebo as adjunctive therapy to an antidepressant in participants with MDD.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Timeframe: Baseline to Week 6
Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
Timeframe: Up to Week 8
Percentage of Participants With Clinically Significant Laboratory Abnormalities
Timeframe: Up to Week 8
Change From Baseline in Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) at Day 8
Timeframe: Baseline and Day 8
Change From Baseline in Vital Signs (SBP and DBP) at Day 22
Timeframe: Baseline and Day 22
Change From Baseline in Vital Signs (SBP and DBP) at Day 42
Timeframe: Baseline and Day 42
Change From Baseline in Vital Signs (SBP and DBP) at Endpoint (Week 6)
Timeframe: Baseline and Endpoint (Week 6)
Change From Baseline in Vital Sign (Pulse Rate [PR]) at Day 8
Timeframe: Baseline and Day 8
Change From Baseline in Vital Sign (PR) at Day 22
Timeframe: Baseline and Day 22
Change From Baseline in Vital Sign (PR) at Day 42
Timeframe: Baseline and Day 42
Change From Baseline in Vital Sign (PR) at Endpoint (Week 6)
Timeframe: Baseline and Endpoint (Week 6)
Change From Baseline in Vital Sign (Temperature) at Day 8
Timeframe: Baseline and Day 8
Change From Baseline in Vital Sign (Temperature) at Day 22
Timeframe: Baseline and Day 22
Change From Baseline in Vital Sign (Temperature) at Day 42
Timeframe: Baseline and Day 42
Change From Baseline in Vital Sign (Temperature) at Endpoint (Week 6)
Timeframe: Baseline and Endpoint (Week 6)
Change From Baseline in Physical Examination (Waist Circumference) at Day 42
Timeframe: Baseline and Day 42
Change From Baseline in Physical Examination (Body Weight) at Day 42
Timeframe: Baseline and Day 42
Change From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 42
Timeframe: Baseline and Day 42
Percentage of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values Outside Pre-defined Limits
Timeframe: Up to Week 6
Percentage of Participants With Most Severe Post-baseline Potentially Suicide-Related Category Using Columbia Suicide Severity Rating Scale (C-SSRS)
Timeframe: Up to Week 8
Change From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42
Timeframe: Baseline and Day 42
Physician Withdrawal Checklist-20 (PWC-20) Total Score at Day 43
Timeframe: Day 43
Physician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 56
Timeframe: Day 49 to Day 56